Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.79 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.78 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11481071 | 1.00 | HDAC1 (0.79) | HDAC1HDAC6DNMT3ANLRP3 | |
| SCHEMBL11487522 | 0.93 | DNMT3A (0.75) | HDAC1HDAC6DNMT3ANLRP3 | |
| SCHEMBL11489672 | 0.92 | HDAC1 (0.78) | HDAC1HDAC6DNMT3ANLRP3 | |
| SCHEMBL11474785 | 0.92 | DNMT3A (0.73) | HDAC1HDAC6DNMT3ANLRP3 | |
| SCHEMBL11471953 | 0.91 | DNMT3A (0.72) | HDAC1HDAC6DNMT3ANLRP3 | |
| SCHEMBL11481498 | 0.91 | DNMT3A (0.72) | HDAC1HDAC6DNMT3ANLRP3 | |
| SCHEMBL11487290 | 0.91 | DNMT3A (0.72) | HDAC1HDAC6DNMT3ANLRP3 | |
| SCHEMBL11356587 | 0.91 | DNMT3A (0.78) | HDAC1HDAC6DNMT3ANLRP3 | |
| SCHEMBL11471028 | 0.91 | HDAC1 (0.79) | HDAC1HDAC6DNMT3ANLRP3 | |
| SCHEMBL11488803 | 0.91 | PPARA (0.67) | HDAC1HDAC6DNMT3ANLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419209-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | Dana-Farber Cancer Institute, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023069943-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |